Molina Healthcare Inc
Molina Healthcare, Inc. is a managed care company that provides health insurance and care management services primarily through Medicaid, Medicare, and Marketplace programs. Founded in 1980 to serve low-income families, it now serves about 5.5 million members across 21 states, with most revenue tied to government-sponsored coverage.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueState-contracted health plans for low-income and eligible members under Medicaid.
Medicare Advantage and related products, including dual-eligible focused offerings.
ACA-compliant individual plans sold through federal and state exchanges.
Long-term services and supports consultative services and small commercial operations.
Customers
Molina's primary customers are state Medicaid agencies and the federal government, which fund or sponsor most of the covered lives. It also serves individual members in the ACA Marketplace, especially low-income subsidized enrollees, and Medicare members, including dual-eligible populations. The company sells through regulated exchange channels and licensed agents, so customer acquisition depends on state contracts, CMS rules, and enrollment periods.
Buy managed care coverage for eligible low-income populations and drive the bulk of Molina's membership and revenue.
Fund and regulate Medicare and Marketplace participation, including risk adjustment and exchange rules.
Purchase ACA exchange plans, often with subsidies, to access affordable compliant coverage.
Buy Medicare products designed for members eligible for both Medicare and Medicaid, a strategic focus area.
Do not buy insurance themselves, but distribute Molina's Medicare and Marketplace products and influence enrollment.
Strategy
Molina's stated priority is organic growth through existing health plan expansion and winning new state territories, with targeted acquisitions considered only when strategically fitting. Management is also shifting Medicare toward dual-eligible members and plans to exit MAPD for 2027, while reducing Marketplace enrollment to restore margins. The strategy reflects a focus on contract quality, pricing discipline, and medical cost control rather than growth at any cost.
State contract wins and footprint expansion are the main growth engine and leverage existing capabilities.
Exiting MAPD and focusing on dual-eligible members should improve strategic fit and margin quality.
Reducing enrollment and tightening pricing is intended to offset elevated medical cost trends and risk adjustment pressure.
Maintaining liquidity and returning excess capital supports flexibility while meeting statutory capital needs.
Geography
Molina operates in 21 U.S. states, with business concentrated in state-by-state Medicaid, Medicare, and Marketplace contracts rather than a single national market. The company also noted that its Marketplace participation in 2026 excludes several states, underscoring that geography is shaped by regulatory approvals, state contracts, and local medical cost trends. Wisconsin is specifically mentioned for long-term services and supports consultative services, and the ConnectiCare acquisition added commercial exposure in 2025.
Risks
Molina is exposed to medical cost inflation, utilization spikes, and state/federal rate-setting that can lag actual claims trends, especially in Medicaid and Marketplace. Its earnings are also sensitive to regulatory changes, risk adjustment, program integrity actions, and contract losses, while cyber and data privacy incidents could disrupt operations and trigger regulatory or reputational damage.
- Medicaid rate inadequacyImpact: HighLikelihood: High
States may set rates below actual medical cost trends, compressing margins in Molina's largest business.
Exposure: Medicaid segment
- Medical cost trend and utilization pressureImpact: HighLikelihood: High
Higher acuity and utilization can push medical care ratio above pricing assumptions.
Exposure - Regulatory and policy changeImpact: HighLikelihood: High
Changes to Medicaid, Marketplace subsidies, and CMS program integrity can affect membership and revenue.
Exposure: U.S. government-sponsored programs
- Cybersecurity and data privacyImpact: HighLikelihood: Medium
The company handles sensitive member and business data and relies on third-party vendors and remote systems.
Exposure: Enterprise-wide
- Goodwill and intangible impairmentImpact: MediumLikelihood: Medium
Contract losses, adverse state actions, or weaker performance could trigger non-cash impairment charges.
Exposure: Acquired businesses and reporting units
Accounting
Judgemental itemsReserve estimates depend on utilization, acuity, and lagged claims data, directly affecting medical care ratio and earnings.
Impact: Can materially change operating income and net income
Government-sponsored programs require estimates for amounts due to agencies and risk transfers, which can move revenue and expense timing.
Impact: Affects premium revenue, receivables/payables, and margin
Acquisitions create goodwill that must be tested for impairment if performance or contract assumptions weaken.
Impact: Potential non-cash impairment charges
Premium tax revenue and expense are significant and vary with state mix and program structure.
Impact: Affects reported revenue, expenses, and pre-tax margin
Operating and finance leases create contractual obligations and affect balance sheet liabilities and expense recognition.
Impact: Impacts operating expenses and leverage metrics
Similar listed companies
Publicly listed companies with a comparable business focus.
Clover Health Investments, Corp
CLOV · Hospital & Medical Service Plans
Alignment Healthcare, Inc.
ALHC · Hospital & Medical Service Plans
Moderna, Inc.
MRNA · Biological Products, (No Diagnostic Substances)
HCA Healthcare, Inc.
HCA · Services-General Medical & Surgical Hospitals, NEC
HCA Healthcare operates a large network of acute-care hospitals, behavioral hospitals, rehabilitation hospitals, ambulatory surgery centers, and endoscopy…
Humana Inc
HUM · Hospital & Medical Service Plans
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Last updated: 24/09/2026